Key Points
- CEO Shao-Lee Lin sold 18,258 Cue Biopharma shares at an average price of $28.62, generating $522,543.96. The sale was made to cover tax withholding on vested equity awards, leaving Lin with 705,995 shares.
- Cue Biopharma shares opened at $34.20 after rising 10%, but the company reported a quarterly loss of $24.14 per share, far below the $1.69 consensus estimate, despite revenue of $7.88 million exceeding expectations.
- Analyst sentiment remains negative: the stock has a consensus “Sell” rating, while institutional investors and hedge funds collectively own 35.04% of the company.
Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) CEO Shao-Lee Lin sold 18,258 shares of the business's stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $28.62, for a total transaction of $522,543.96. Following the completion of the sale, the chief executive officer owned 705,995 shares in the company, valued at $20,205,576.90. This represents a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Shao-Lee Lin also recently made the following trade(s):
- On Wednesday, August 12th, Shao-Lee Lin sold 40,000 shares of Cue Biopharma stock. The shares were sold at an average price of $27.10, for a total transaction of $1,084,000.00.
Cue Biopharma Trading Up 10.0%
NASDAQ:CUE opened at $34.20 on Friday. The company has a market capitalization of $143.64 million, a P/E ratio of -6.12 and a beta of 2.47. The firm has a 50-day moving average price of $29.50 and a two-hundred day moving average price of $147.28. Cue Biopharma, Inc. has a twelve month low of $4.97 and a twelve month high of $45.50.
Cue Biopharma (NASDAQ:CUE - Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($22.45). The business had revenue of $7.88 million during the quarter, compared to analysts' expectations of $3.00 million. Cue Biopharma had a negative net margin of 59.65% and a negative return on equity of 98.30%.
Analyst Upgrades and Downgrades
A number of brokerages have commented on CUE. Weiss Ratings upgraded Cue Biopharma from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, May 18th. Wall Street Zen cut Cue Biopharma from a "buy" rating to a "hold" rating in a report on Saturday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of "Sell".
Check Out Our Latest Report on CUE
Institutional Trading of Cue Biopharma
Hedge funds have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. grew its stake in Cue Biopharma by 730.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company's stock worth $57,000 after acquiring an additional 73,000 shares during the period. Squarepoint Ops LLC purchased a new position in shares of Cue Biopharma during the 3rd quarter worth $62,000. Stifel Financial Corp boosted its holdings in shares of Cue Biopharma by 25.4% during the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company's stock worth $75,000 after purchasing an additional 50,000 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc boosted its holdings in shares of Cue Biopharma by 1,231.2% during the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company's stock worth $135,000 after purchasing an additional 407,568 shares during the last quarter. Finally, Boothbay Fund Management LLC grew its position in shares of Cue Biopharma by 15.3% in the fourth quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company's stock valued at $215,000 after purchasing an additional 93,333 shares during the period. Institutional investors and hedge funds own 35.04% of the company's stock.
About Cue Biopharma
(
Get Free Report)
Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company's proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.
Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
